Abstract
A series of di-substituted cinnamic hydroxamic derivatives was designed, synthesized and evaluated as HDAC inhibitors. Compound 5f (HS270) demonstrated potent HDAC inhibitory and antiproliferative activities. In xenograft model, 5f showed significant antitumor efficacy in tumorbearing mice.
Keywords: Antitumor, cinnamic, design, histone deacetylase, HDAC, hydroxamaic acid.
Letters in Drug Design & Discovery
Title:Discovery of Novel HDAC Inhibitors by Structure-based Optimization of Cinnamic Hydroxamic Scaffold
Volume: 12 Issue: 5
Author(s): Chengqing Ning, Wenyuan Huang, Wen Wu, Cheng Lu, Yujun He, Lei Yao, Lifei Liu, Xiaohe Zhen, Xiaoyu Liu and Niefang Yu
Affiliation:
Keywords: Antitumor, cinnamic, design, histone deacetylase, HDAC, hydroxamaic acid.
Abstract: A series of di-substituted cinnamic hydroxamic derivatives was designed, synthesized and evaluated as HDAC inhibitors. Compound 5f (HS270) demonstrated potent HDAC inhibitory and antiproliferative activities. In xenograft model, 5f showed significant antitumor efficacy in tumorbearing mice.
Export Options
About this article
Cite this article as:
Ning Chengqing, Huang Wenyuan, Wu Wen, Lu Cheng, He Yujun, Yao Lei, Liu Lifei, Zhen Xiaohe, Liu Xiaoyu and Yu Niefang, Discovery of Novel HDAC Inhibitors by Structure-based Optimization of Cinnamic Hydroxamic Scaffold, Letters in Drug Design & Discovery 2015; 12 (5) . https://dx.doi.org/10.2174/1570180811666141024004832
DOI https://dx.doi.org/10.2174/1570180811666141024004832 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Immune Responses to Gene-Modified T Cells
Current Gene Therapy Targeted Strategies in the Treatment of Primary Gastric Lymphomas: From Rituximab to Recent Insights into Potential New Drugs
Current Medicinal Chemistry Dequalinium-Derived Nanoconstructs: A Promising Vehicle for Mitochondrial Targeting
Current Drug Delivery Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses
Recent Patents on Anti-Cancer Drug Discovery Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency
Current Drug Safety Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Current Pharmaceutical Design The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma
Current Drug Targets Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton’s Jelly Cells
Recent Patents on Regenerative Medicine Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets